552 related articles for article (PubMed ID: 25267524)
21. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
22. Treatment of newly diagnosed myeloma.
Palumbo A; Rajkumar SV
Leukemia; 2009 Mar; 23(3):449-56. PubMed ID: 19005483
[TBL] [Abstract][Full Text] [Related]
23. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Martin TG
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
[TBL] [Abstract][Full Text] [Related]
24. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
25. Current status of bortezomib in the treatment of multiple myeloma.
Cavo M
Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Dimopoulos MA; Beksac M; Benboubker L; Roddie H; Allietta N; Broer E; Couturier C; Mazier MA; Angermund R; Facon T
Haematologica; 2013 Aug; 98(8):1264-72. PubMed ID: 23716559
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
28. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
29. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
[No Abstract] [Full Text] [Related]
30. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
[TBL] [Abstract][Full Text] [Related]
31. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
32. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
35. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
Badros AZ; Vij R; Martin T; Zonder JA; Kunkel L; Wang Z; Lee S; Wong AF; Niesvizky R
Leukemia; 2013 Aug; 27(8):1707-14. PubMed ID: 23364621
[TBL] [Abstract][Full Text] [Related]
36. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Ludwig H; Zojer N
Nat Rev Clin Oncol; 2010 May; 7(5):289-94. PubMed ID: 20351701
[TBL] [Abstract][Full Text] [Related]
37. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Scheid C; Sonneveld P; Schmidt-Wolf IG; van der Holt B; el Jarari L; Bertsch U; Salwender H; Zweegman S; Blau IW; Vellenga E; Weisel K; Pfreundschuh M; Jie KS; Neben K; van de Velde H; Duehrsen U; Schaafsma MR; Lindemann W; Kersten MJ; Peter N; Hänel M; Croockewit S; Martin H; Wittebol S; Bos GM; van Marwijk-Kooy M; Wijermans P; Goldschmidt H; Lokhorst HM
Haematologica; 2014 Jan; 99(1):148-54. PubMed ID: 23996482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]